# US 2020/0368330 A1 · Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0368330 A1
- Document ID: US20200368330A1
- Status: Published application
- Kind: A1
- Application number: 16/930,766
- Filed: 2020-07-16
- Published: 2020-11-26
- Earliest claimed: 2008-04-14
- Assignees: Halozyme, Inc.
- Applicants: Halozyme, Inc.
- Inventors: Gregory I. Frost; Ping Jiang; Curtis B. Thompson
- Web page: https://patentgrep.com/patent/US20200368330A1

## CPC

- A61K 38/47: acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A61K 31/337: having four-membered rings, e.g. taxol
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/10: Antioedematous agents; Diuretics
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C12N 9/2408: {acting on alpha -1,4-glucosidic bonds}
- C12N 11/089: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- C12N 11/096: Polyesters; Polyamides
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided are combinations, compositions and kits containing a hyaluronan degrading enzyme, such as a soluble hyaluronidase, for treatment of hyaluronan-associated conditions, diseases and disorders. In one example, the products include an additional agent or treatment. Such products can be used in methods for administering the products to treat the hyaluronan-associated diseases and conditions, for example, hyaluronan-associated cancers, for example, hyaluronan-rich tumors. The methods include administration of the hyaluronan degrading enzyme composition alone or in combination with other treatments. Also provided are methods and compositions for providing sustained treatment effects in hyaluronan-associated diseases and conditions.

## Claims

### Claim 1

A method for treating a tumor with a polymer-conjugated soluble human PH20 hyaluronidase in a subject having cancer, comprising:
a) measuring the expression or level of hyaluronan in a tumor sample from the subject; and the tumor sample is a tumor biopsy sample;
b) determining the level of expression of hyaluronan in the tumor biopsy sample;
c) identifying, for treatment, the subject, wherein hyaluronan is expressed in at least 30% of the tumoral area in the tumor biopsy sample from the subject; and then
d) administering to the subject, the polymer-conjugated soluble hyaluronidase.

### Claim 2 (depends on 1)

The method of claim 1, wherein the polymer-conjugated soluble human PH20 is a PEGylated PH20 (PEGPH20).

### Claim 3 (depends on 1)

The method of claim 1, wherein the cancer is selected from among ovarian cancer, in situ carcinoma (ISC), squamous cell carcinoma (SCC), prostate cancer, gastric cancer, non-small cell lung cancer, breast cancer, brain cancer and colon cancer.

### Claim 4 (depends on 1)

The method of claim 1, further comprising administering a second agent that is an anti-cancer agent or treatment for treating the tumor in the subject.

### Claim 5 (depends on 1)

The method of claim 1, wherein the polymer-conjugated soluble hyaluronidase is a C-terminally truncated human PH20 hyaluronidase that lacks all or a portion of a C-terminal glycosylphosphatidylinositol (GPI) anchor.

### Claim 6 (depends on 1)

The method of claim 1, wherein the polymer-conjugated soluble PH20 hyaluronidase is a polypeptide consisting of an amino acid sequence having at least 98% amino acid sequence identity with the amino acid sequence of SEQ ID NO:48, wherein the soluble PH20 hyaluronidase is N-glycosylated and neutral active.

### Claim 7 (depends on 1)

The method of claim 1, wherein the polymer-conjugated soluble PH20 hyaluronidase consists of the amino acid sequence set forth as amino acids 36-467, 36-468, 36-469, 36-470, 36-471, 36-472, 36-473, 36-474, 36-475, 36-476, 36-477, 36-478, 36-479, 36-480, 36-481, 36-482, or 36-483 of the amino acid sequence of SEQ ID NO:1, or an amino acid sequence having at least 95% amino acid sequence identity with the amino acid sequence set forth as amino acids 36-467, 36-468, 36-469, 36-470, 36-471, 36-472, 36-473, 36-474, 36-475, 36-476, 36-477, 36-478, 36-479, 36-480, 36-481, 36-482, or 36-483 of the amino acid sequence of SEQ ID NO:1.

### Claim 8 (depends on 1)

The method of claim 1, wherein the polymer-conjugated soluble hyaluronidase is a PEGylated soluble PH20 hyaluronidase, wherein the soluble PH20 hyaluronidase is selected from among a polypeptide consisting of the amino acid sequence set forth in SEQ ID NOs: 4-9 and 47-48, or variants thereof that have at least 98% amino acid sequence identity to the amino acid sequence of SEQ ID NO:48.

### Claim 9 (depends on 1)

The method of claim 1, wherein:
the polymer-conjugated soluble hyaluronidase is PEGylated; and
PEGylation results from reaction with a PEG reagent selected from methoxy-poly(ethylene glycol)-succinimidyl butanoate (mPEG-SBA) (5 kDa); methoxy-poly(ethylene glycol)-succinimidyl butanoate (mPEG-SBA) (20 kDa); methoxy-poly(ethylene glycol)-succinimidyl butanoate (mPEG-SBA) (30 kDa); methoxy-poly(ethylene glycol)-succinimidyl α-methylbutanoate (mPEG-SMB) (20 kDa); methoxy-poly(ethylene glycol)-succinimidyl α-methylbutanoate (mPEG-SMB) (30 kDa); methoxy-poly(ethylene glycol)-butyraldehyde (mPEG-butyraldehyde) (30 kDa), methoxy-poly(ethylene glycol)-succinimidyl propionate (mPEG-SPA) (20 kDa); methoxy-poly(ethylene glycol)-succinimidyl propionate (mPEG-SPA) (30 kDa); (methoxy-poly(ethylene glycol)) 2-N-hydroxysuccinimide ester (mPEG2-NHS) (10 kDa branched); (methoxy-poly(ethylene glycol)) 2-N-hydroxysuccinimide ester (mPEG2-NHS) (20 kDa branched); (methoxy-poly(ethylene glycol)) 2-N-hydroxysuccinimide ester (mPEG2-NHS) (40 kDa branched); (methoxy-poly(ethylene glycol)) 2-N-hydroxysuccinimide ester (mPEG2-NHS) (60 kDa branched); biotin-poly(ethylene glycol)-N-hydroxysuccinimide ester (biotin-PEG-NHS) (5 kDa biotinylated); poly(ethylene glycol)-p-nitrophenyl carbonate (PEG-p-nitrophenyl-carbonate) (30 kDa); and poly(ethylene glycol)-propionaldehyde (PEG-propionaldehyde) (30 kDa).

### Claim 10 (depends on 1)

The method of claim 1, wherein:
the polymer-conjugated soluble hyaluronidase is PEGylated; and
the PEG is a branched or linear PEG.

### Claim 11 (depends on 1)

The method of claim 1, wherein:
the polymer-conjugated soluble hyaluronidase is PEGylated; and
the PEG has a mass of at least about 30 kilodaltons.

### Claim 12 (depends on 1)

The method of claim 1, wherein the polymer-conjugated soluble PH20 hyaluronidase is administered intravenously, subcutaneously, intraperitoneally, or intra-tumorally.

### Claim 13 (depends on 1)

The method of claim 1, wherein the polymer-conjugated soluble PH20 hyaluronidase is administered at a dose of 10 to 50,000,000 Units.

### Claim 14

A method for treating a disease or condition in which a hyaluronidase substrate accumulates, comprising:
administering a soluble hyaluronidase enzyme to a subject at least once a week for a predetermined number of weeks in an amount sufficient to maintain a pharmacologically active level of the hyaluronidase in the plasma of at least about or 3 U/mL to prevent resynthesis of the substrate, hyaluronan, to levels prior to treatment, wherein:
the hyaluronidase enzyme is modified by conjugation to a polymer; and
the predetermined number of weeks is more than one week.

### Claim 15 (depends on 14)

The method of claim 14, wherein the predetermined number of weeks is at least two weeks.

### Claim 16 (depends on 14)

The method of claim 14, wheren the predetermined number of weeks is at least four weeks.

### Claim 17 (depends on 14)

The method of claim 14, wherein after the predetermined number of weeks, administration is discontinued for a first predetermined period of time, and then resumed for at least one week.

### Claim 18 (depends on 17)

The method of claim claim 17, wherein the cycle of administration and discontinuation of adminstration is repeated a plurality of times.

### Claim 19 (depends on 14)

The method of claim 14, wherein the hyaluronidase is administered in an amount sufficient to maintain a pharmacologically active level of the hyaluronidase in the plasma of at least or about 3 U/mL-12 U/mL.

### Claim 20 (depends on 14)

The method of claim 14, wherein the hyaluronidase is administered twice a week.

### Claim 21 (depends on 14)

The method of claim 14, wherein a single dose of hyaluronidase is 0.05 mg/kg-0.8 mg/kg.

### Claim 22 (depends on 14)

The method of claim 14, wherein:
hyaluronan expression in a sample from the subject is measured prior to treatment; and
if the hyaluronan is elevated and at a level indicative of the disease or condition, the soluble hyaluronidase enzyme is administered to treat a disease or condition in which hyaluronan accumulates.

### Claim 23 (depends on 22)

The method of claim 22, wherein the sample from the subject is a tissue or body fluid.

### Claim 24 (depends on 23)

The method of claim 23, wherein the sample from the subject is a blood sample, tumor biopsy, cerebral spinal fluid, urine, sweat, semen or saliva sample.

### Claim 25 (depends on 14)

The method of claim 14, wherein the disease or condition is a disease or condition associated with elevated interstitial fluid pressure, decreased vascular volume, or increased water content in a tissue.

### Claim 26 (depends on 14)

The method of claim 14, wherein the hyaluronidase is a polymer-conjugated soluble PH20 hyaluronidase.

### Claim 27 (depends on 25)

The method of claim 25, wherein the the disease or condition is a cancer, disc pressure, or edema.

### Claim 28 (depends on 27)

The method of claim 27, wherein the disease or condition is edema, and the edema is caused by organ transplant, stroke or brain trauma.

### Claim 29 (depends on 14)

The method of claim 14, wherein the disease or condition is cancer, and the cancer is a tumor that has increased cellular and/or stromal expression of a hyaluronan, compared to a non-cancerous tissue of the same tissue type or compared to a non-metastatic tumor of the same tumor-type.

### Claim 30 (depends on 29)

The method of claim 29, wherein:
the disease or condition is selected from among any one or more of ovarian cancer, in situ carcinoma (ISC), squamous cell carcinoma (SCC), prostate cancer, non-small cell lung cancer, breast cancer, brain cancer and colon cancer.

### Claim 31 (depends on 26)

The method of claim 26, wherein the soluble form of PH20 is a truncated human PH20 lacking all or a portion of a C-terminal GPI anchor.

### Claim 32 (depends on 26)

The method of claim 26, wherein the polymer-conjugated soluble PH20 hyaluronidase consists of the polymer and a polypeptide consisting of an amino acid sequence having at least 98% amino acid sequence identity with the amino acid sequence of SEQ ID NO:48, wherein the soluble PH20 hyaluronidase is N-glycosylated and neutral active.

### Claim 33 (depends on 26)

The method of claim 26, wherein the polymer-conjugated soluble PH20 hyaluronidase consists of the amino acid sequence set forth as amino acids 36-467, 36-468, 36-469, 36-470, 36-471, 36-472, 36-473, 36-474, 36-475, 36-476, 36-477, 36-478, 36-479, 36-480, 36-481, 36-482, or 36-483 of the amino acid sequence of SEQ ID NO:1, or an amino acid sequence having at least 95% amino acid sequence identity with the amino acid sequence set forth as amino acids 36-467, 36-468, 36-469, 36-470, 36-471, 36-472, 36-473, 36-474, 36-475, 36-476, 36-477, 36-478, 36-479, 36-480, 36-481, 36-482, or 36-483 of the amino acid sequence of SEQ ID NO:1.

### Claim 34 (depends on 14)

The method of claim 14, wherein:
the soluble hyaluronidase is a PEGylated soluble PH20 hyaluronidase; and
the soluble PH20 hyaluronidase is selected from among a polypeptide consisting of the amino acid sequence set forth in SEQ ID NOs: 4-9 and 47-48, or variants thereof that have at least 98% amino acid sequence identity to the amino acid sequence of SEQ ID NO:48.

### Claim 35 (depends on 14)

The method of claim 14, wherein:
the soluble hyaluronidase is PEGylated; and
PEGylation results from reaction with a PEG reagent selected from methoxy-poly(ethylene glycol)-succinimidyl butanoate (mPEG-SBA) (5 kDa); methoxy-poly(ethylene glycol)-succinimidyl butanoate (mPEG-SBA) (20 kDa); methoxy-poly(ethylene glycol)-succinimidyl butanoate (mPEG-SBA) (30 kDa); methoxy-poly(ethylene glycol)-succinimidyl a-methylbutanoate (mPEG-SMB) (20 kDa);
methoxy-poly(ethylene glycol)-succinimidyl a-methylbutanoate (mPEG-SMB) (30 kDa); methoxy-poly(ethylene glycol)-butyraldehyde (mPEG-butyraldehyde) (30 kDa), methoxy-poly(ethylene glycol)-succinimidyl propionate (mPEG-SPA) (20 kDa); methoxy-poly(ethylene glycol)-succinimidyl propionate (mPEG-SPA) (30 kDa); (methoxy-poly(ethylene glycol)) 2-N-hydroxysuccinimide ester (mPEG2-NHS) (10 kDa branched); (methoxy-poly(ethylene glycol)) 2-N-hydroxysuccinimide ester (mPEG2-NHS) (20 kDa branched); (methoxy-poly(ethylene glycol)) 2-N-hydroxysuccinimide ester (mPEG2-NHS) (40 kDa branched); (methoxy-poly(ethylene glycol)) 2-N-hydroxysuccinimide ester (mPEG2-NHS) (60 kDa branched); biotin-poly(ethylene glycol)-N-hydroxysuccinimide ester (biotin-PEG-NHS) (5 kDa biotinylated); poly(ethylene glycol)-p-nitrophenyl carbonate (PEG-p-nitrophenyl-carbonate) (30 kDa); and poly(ethylene glycol)- propionaldehyde (PEG-propionaldehyde) (30 kDa).

### Claim 36 (depends on 14)

The method of claim 14, wherein:
the polymer-conjugated soluble hyaluronidase is PEGylated; and
the PEG is a branched or linear PEG.

### Claim 37 (depends on 35)

The method of claim 35, wherein:
the polymer-conjugated soluble hyaluronidase is PEGylated; and
the PEG is a methoxy-PEG (mPEG), or is a linear N-hydroxysuccinimidyl ester of methoxy poly(ethylene glycol) butanoic acid.
